B
Byoung Chul Cho
Researcher at Yonsei University
Publications - 570
Citations - 23868
Byoung Chul Cho is an academic researcher from Yonsei University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 57, co-authored 429 publications receiving 15603 citations. Previous affiliations of Byoung Chul Cho include University Health System & AstraZeneca.
Papers
More filters
Journal ArticleDOI
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042
Roy S. Herbst,G. Lopes,Dariusz M. Kowalski,Kazuo Kasahara,Y-L. Wu,G. De Castro,Byoung Chul Cho,Hande Turna,Razvan Cristescu,Deepti Aurora-Garg,Jared Lunceford,J. Kobie,M. Ayers,M.C. Pietanza,Bilal Piperdi,Tony Mok +15 more
TL;DR: It is suggested that pembrolizumab monotherapy should be considered as a standard first-line treatment option for PD-L1-positive advanced non-squamous NSCLC regardless of KRAS mutational status, and that a pembrosumab-containing regimen is a clinically relevant comparator for studies ofKRAS -targeted therapy.
Journal ArticleDOI
Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).
Byoung Chul Cho,Alexander Drilon,Robert C. Doebele,Dong Wan Kim,Jessica J. Lin,Jeeyun Lee,Myung-Ju Ahn,Viola W. Zhu,Samuel Ejadi,D. Ross Camidge,Yuwei Juliet Liu,Shanna Stopatschinskaja,Jingrong Jean Cui,David M. Hyman,Sai-Hong Ignatius Ou,Alice T. Shaw +15 more
TL;DR: Repotrectinib is a next-generation ROS1/TRK/ALK TKI inhibiting ROS1 with > 90-fold greater potency than crizotinib and preclinical studies showed robust kinase inhibitory activity of this drug.
Journal ArticleDOI
Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.
D. Ross Camidge,Solange Peters,Tony Mok,Shirish M. Gadgeel,Parneet K. Cheema,Nick Pavlakis,Filippo de Marinis,Daniil Stroyakovskiy,Byoung Chul Cho,Li Zhang,Denis Moro-Sibilot,Ali Zeaiter,Emmanuel Mitry,Bogdana Balas,Barbara Muller,Alice T. Shaw +15 more
TL;DR: The primary ALEX (NCT02075840) analysis showed superior investigator (INV)-assessed PFS with ALC vs CZ showed superior results compared with the control group (CZ).
Journal ArticleDOI
Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study
Sung Hee Lim,Jong Mu Sun,Yoon-La Choi,Hye Ryun Kim,Soomin Ahn,Ji Yun Lee,Se-Hoon Lee,Jin Seok Ahn,Keunchil Park,Joo Hang Kim,Byoung Chul Cho,Myung-Ju Ahn +11 more
TL;DR: The current phase 2 study evaluated the efficacy and tolerability of dovitinib, an FGFR inhibitor, in patients with advanced SCC of the lung.
Journal ArticleDOI
Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
Justin F. Gainor,Giuseppe Curigliano,Dong Wan Kim,Dae Ho Lee,Benjamin Besse,Christina S. Baik,Robert C. Doebele,Philippe A. Cassier,Gilberto Lopes,Daniel Shao-Weng Tan,Elena Garralda,Luis Paz-Ares,Byoung Chul Cho,Shirish M. Gadgeel,Michael Thomas,Stephen V. Liu,Corinne Clifford,Hui Zhang,Christopher D. Turner,Vivek Subbiah +19 more
TL;DR: Pralsetinib is an investigational, highly potent, selective RET kinase inhibitor targeting oncogenic RET alterations and provides the registrational dataset for pts with RET fusion+ RET alterations.